Advertisement
Advertisement
ARVN
Arvinas, Inc
6.92
USDSponsored
+0.16
+2.37%
Nov 10, 15:59 UTC -5
Closed
After-Market
6.72
-0.20
-2.89%
Arvinas, Inc (ARVN) Earnings
ARVN Earnings Reports
Positive Surprise Ratio
ARVN beat 17 of 33 last estimates.
52%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$14.46M
/-$0.91
Implied change from Q3 26 (Revenue/ EPS)
+2792.21%
/+10.98%
Implied change from Q4 25 (Revenue/ EPS)
+52.22%
/-17.27%
Arvinas, Inc earnings per share and revenue
On Nov 03, 2026, ARVN reported earnings of -0.82 USD per share (EPS) for Q3 26, beating the estimate of -0.88 USD, resulting in a 7.71% surprise. Revenue reached 500.00 thousand, compared to an expected 22.94 million, with a -97.82% difference. The market reacted with a -5.72% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.91 USD, with revenue projected to reach 14.46 million USD, implying an increase of 10.98% EPS, and increase of 2792.21% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Arvinas, Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Arvinas, Inc reported EPS of -$0.82, beating estimates by 7.71%, and revenue of $500.00K, -97.82% below expectations.
How did the market react to Arvinas, Inc's Q3 2026 earnings?
The stock price moved down -5.72%, changed from $7.52 before the earnings release to $7.09 the day after.
When is Arvinas, Inc expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Arvinas, Inc's next earnings report?
Based on --
analysts, Arvinas, Inc is expected to report EPS of -$0.91 and revenue of $14.46M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.